Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
SurVaxM by MimiVax for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
SurVaxM is under clinical development by MimiVax and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData,...
Data Insights
SurVaxM by MimiVax for Glioblastoma Multiforme (GBM): Likelihood of Approval
SurVaxM is under clinical development by MimiVax and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...